alpha 1 adrenoceptor Inhibitors
1 drugsAbout alpha 1 adrenoceptor
The alpha 1 adrenoceptor (α1-adrenergic receptor) mediates norepinephrine and epinephrine effects, leading to vasoconstriction and increased blood pressure. As a receptor protein, it is a key target in cardiovascular drug development.
Modulation of this receptor has proven clinically relevant. However, there is currently no genetic evidence directly linking variations in the gene encoding the alpha 1 adrenoceptor to specific diseases.
The alpha 1 adrenoceptor is targeted by one FDA-approved drug, CARDURA (doxazosin), a small molecule developed by Viatris. It was first approved in 1990 for cardiovascular indications.
Top alpha 1 adrenoceptor Drugs
Viatris is the only company with an approved drug targeting the alpha 1 adrenoceptor.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
alpha 1 adrenoceptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 1 adrenoceptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage in this space.
alpha 1 adrenoceptor Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 1 adrenoceptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 6 | 4 | 0 | 1 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1 adrenoceptor Drug Approval Timeline (1990 - 1990)
The first and only drug, CARDURA, was approved in 1990.
The lack of recent approvals suggests a saturated market or challenges in developing new alpha 1 adrenoceptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 1 adrenoceptor. A trial counts if an approved drug acting on alpha 1 adrenoceptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.